5 Facts in MDS
Myelodysplastic Syndromes (MDS) are a rare group of bone marrow failure disorders
More... |
CE Education
Current and Emerging Treatments for Myelodysplastic Syndromes
Mikkael A. Sekeres, MD, MS, and Amy E. DeZern, MD, MHS |
CE Education
Current and Future Perspectives in the Treatment of High-risk MDS
Richard Stone, MD |
Newsletters
Treatment Options for Low- and High-Risk Patients Based on the Prognostic Information Obtained
Hetty E. Carraway, MD, MBA, FACP |
Clinical Case Snapshots
Defining Risk in MDS
Guillermo Garcia-Manero, MD |
Clinical Commentaries
Experts Discuss DACOTA Phase 3 Trial of Decitabine versus Hydroxyurea for Advanced Proliferative CMML
Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD |
CE Education
How I Approach MDS Diagnosis and Risk Assessment
Hetty E. Carraway, MD, MBA, FACP |
Frequently Asked Questions
What is the clinical significance of SF3B1 in MDS and what are the key points I need to be aware of to determine treatment and outcome of these patients?
Rami S. Komrokji, MD |
